Lantern Pharma Inc.
LTRN
$1.77
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.19% | 15.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.02% | -18.98% | |||
| Operating Income | -3.02% | 18.98% | |||
| Income Before Tax | -112.43% | 18.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -112.43% | 18.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -112.43% | 18.29% | |||
| EBIT | -3.02% | 18.98% | |||
| EBITDA | -3.03% | 18.99% | |||
| EPS Basic | -92.46% | 17.83% | |||
| Normalized Basic EPS | -95.93% | 19.15% | |||
| EPS Diluted | -92.46% | 17.83% | |||
| Normalized Diluted EPS | -95.93% | 19.15% | |||
| Average Basic Shares Outstanding | 10.40% | -0.57% | |||
| Average Diluted Shares Outstanding | 10.40% | -0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||